Cambridge Investment Research Advisors
OMIC

Cambridge Investment Research Advisors’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Cambridge Investment Research Advisors’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-878
Closed -$12K – 3415
2023
Q4 		$12K Hold
878
– – ﹤0.01% 3163
2023
Q3 		$10K Hold
878
– – ﹤0.01% 3115
2023
Q2 		$22K Hold
878
– – ﹤0.01% 3120
2023
Q1 		$32K Buy
+878
New +$53.8K ﹤0.01% 3079

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
QM
QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Cambridge Investment Research Advisors's OMIC Position: Q1 2024 in Review

Cambridge Investment Research Advisors sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2024, closing a stake of 878 shares — an estimated $12K sold.

Cambridge Investment Research Advisors first reported a position in OMIC in Q1 2023 and held it in 4 quarters. The position peaked at $32K in Q1 2023. 42 funds tracked by Wall St. Rank hold OMIC as of Q1 2024.

  • Cambridge Investment Research Advisors reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 878 Singular Genomics Systems, Inc. Common Stock shares in Q1 2024, an estimated $12K.
  • Cambridge Investment Research Advisors first reported a position in Singular Genomics Systems, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Singular Genomics Systems, Inc. Common Stock position peaked at $32K in Q1 2023.
  • 42 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.